Back to Stakeholders
Categories

1 domain / 1 area / 1 specialization

ADAR1 Capital Management

Also known as: ADAR1, ADAR1 Capital Management, LLC

Data updated

Austin, Texas, United States

ADAR1 Capital Management is an Austin-based investment manager focused on public and private equity investments in life sciences and biotechnology. Public adviser and investor materials point to a specialist healthcare and biotech orientation.

ADAR1's relevance to psychedelic medicine is source-backed through atai's 2025 private placement. The record is useful for mapping public-market and crossover healthcare capital around psychedelic mental-health drug development.

Investor Context

Institutional Investors

Investment Context

This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Public Markets and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

ADAR1 Capital Management is included as a life-science and biotechnology investment manager with a confirmed atai financing record. It should be understood as healthcare/public-market capital with psychedelic-adjacent exposure through atai rather than a dedicated psychedelics fund.

Investor Type

Institutional Investor

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

Public MarketsGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Institutional Investor

Investment Website

Portfolio Stakeholders

Recorded Investments

Private placement financing - approximately $50 million

Direct atai participation; clear source-backed psychedelic therapeutics relevance.

atai Life Sciences Announces $50 Million Private Placement Financing

Quick Facts

Founded
2019
HQ
Austin, Texas, United States
Website
Visit